Related Experiment Video
Updated: Nov 29, 2025
06:21
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
11.8K
Senescence Inflames the Pancreatic Tumor Microenvironment
Giulia Petroni1, Lorenzo Galluzzi1,2,3,4,5
1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Cell Reports. Medicine
|November 18, 2020
Summary
Inducing senescence in pancreatic cancer with MEK and CDK4/CDK6 inhibitors improves tumor blood vessel formation. This enhances the infiltration of CD8+ T cells, making pancreatic adenocarcinomas potentially more responsive to therapy.
Area of Science:
- Oncology
- Cancer Biology
- Immunotherapy
Background:
- Pancreatic adenocarcinomas (PDACs) exhibit poor vascularization, limiting the efficacy of chemotherapy and immunotherapy.
- Therapeutic resistance in PDAC is a significant clinical challenge.
Discussion:
- Lowe and collaborators report that inducing cellular senescence via MEK and CDK4/CDK6 inhibition can overcome PDAC's poor vascularization.
- Senescence induction promotes tumor revascularization, creating a more permissive microenvironment.
Key Insights:
- Targeting senescence pathways with MEK plus CDK4/CDK6 inhibitors facilitates PDAC revascularization.
- Enhanced vascularization correlates with increased infiltration of therapeutically relevant CD8+ T cells into the tumor.
- This approach presents a novel strategy to enhance anti-tumor immunity in pancreatic cancer.
Outlook:
- Combining senescence inducers with immunotherapies or chemotherapies may improve treatment outcomes for pancreatic cancer.
- Further research is warranted to explore the clinical translatability of senescence-based strategies in PDAC.
